Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Amazon, Berkshire, JPMorgan create healthcare company to cut costs Inc., Berkshire Hathaway and JPMorgan Chase & Co. will form a healthcare company aimed at cutting costs for their U.S. employees, they said on Tuesday, sending shares in the broad healthcare sector sharply lower.

Read More »

Corbus CF drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function.

Read More »

Sanofi Acquires Ablynx for $4.85 Billion

One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.

Read More »

J&J Reportedly Bows Out of Race for Pfizer’s Consumer Health Business

Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business

Read More »

Biogen buys IND-ready asset from Karyopharm

Biogen acquired an IND-ready asset from Karyopharm Therapeutics for $10 million upfront.

Read More »

J&J takes $13.6 billion charge

Johnson & Johnson said it would take a $13.6 billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

Read More »

Sanofi to buy U.S. hemophilia group Bioverativ

Paris-based Sanofi has acquired Waltham, Mass.-based Bioverativ for about $11.6 billion.

Read More »

Biotech M&A takes off: Sanofi, Celgene spend $20B

Biotech deal activity exploded with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products to their medicine cabinets.

Read More »

5 Healthcare Systems Launching Generics Company

The U.S. Department of Veterans Affairs and Intermountain Healthcare, Ascension, SSM Health and Trinity Health are forming a not-for-profit generic drug company.

Read More »

Juno Explodes on Celgene Takeover Rumors

Rumors that Celgene Corporation is in talks to acquire Juno Therapeutics caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom